Well put, shareholders see the facts - no data and no trial but the company is proceeding with HBV with the the exact same science and approach. They didn't say if any aspect of future trials is data dependent. They didn't feel it was necessary to reaffirm implicit confidence in the science and the overall time schedule hasn't changed. It's kjust that HCV has stopped.
Sorry for all the posts - I am going now. My weekend is again ruined by another disastrous week.
When a stock is destroyed like this I want plenty of discussion prior to the conference call.
BLT Price at posting:
13.0¢ Sentiment: None Disclosure: Held
